IN2015DN03039A - - Google Patents

Info

Publication number
IN2015DN03039A
IN2015DN03039A IN3039DEN2015A IN2015DN03039A IN 2015DN03039 A IN2015DN03039 A IN 2015DN03039A IN 3039DEN2015 A IN3039DEN2015 A IN 3039DEN2015A IN 2015DN03039 A IN2015DN03039 A IN 2015DN03039A
Authority
IN
India
Prior art keywords
binding
madcam
disulfide
vivo
rich
Prior art date
Application number
Other languages
English (en)
Inventor
Ashok Bhandari
Dinesh V Patel
Larry C Mattheakis
Original Assignee
Protagonist Therapeutics Inc
Ashok Bhandari
Dinesh V Patel
Larry C Mattheakis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics Inc, Ashok Bhandari, Dinesh V Patel, Larry C Mattheakis filed Critical Protagonist Therapeutics Inc
Publication of IN2015DN03039A publication Critical patent/IN2015DN03039A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3039DEN2015 2012-10-11 2013-10-11 IN2015DN03039A (h)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261712722P 2012-10-11 2012-10-11
US201361807714P 2013-04-02 2013-04-02
US14/050,349 US9273093B2 (en) 2012-10-11 2013-10-10 α4β7 peptide dimer antagonists
PCT/US2013/064439 WO2014059213A1 (en) 2012-10-11 2013-10-11 NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS

Publications (1)

Publication Number Publication Date
IN2015DN03039A true IN2015DN03039A (h) 2015-10-02

Family

ID=50477907

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3039DEN2015 IN2015DN03039A (h) 2012-10-11 2013-10-11

Country Status (13)

Country Link
US (3) US9273093B2 (h)
EP (1) EP2906584B1 (h)
JP (2) JP6480865B2 (h)
KR (1) KR20150084808A (h)
CN (1) CN105102470A (h)
AU (2) AU2013329135B2 (h)
CA (1) CA2888479A1 (h)
HK (1) HK1213583A1 (h)
IL (1) IL238123A0 (h)
IN (1) IN2015DN03039A (h)
NZ (1) NZ706909A (h)
SG (2) SG10201702979SA (h)
WO (1) WO2014059213A1 (h)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP2970505A4 (en) 2013-03-14 2016-10-19 California Inst Biomedical Res SPECIFIC ANTIBODIES AND USES THEREOF
AU2014232954B2 (en) 2013-03-15 2018-08-09 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
US20140294901A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
EP3043824B1 (en) 2013-09-13 2022-07-06 The Scripps Research Institute Modified therapeutic agents and compositions thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AU2015258863B2 (en) 2014-05-16 2019-10-24 Protagonist Therapeutics, Inc. Alpha4beta7 integrin thioether peptide antagonists
AU2015289642B2 (en) 2014-07-17 2021-02-25 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
CN106999537B (zh) 2014-10-01 2020-01-31 领导医疗有限公司 新颖α4β7肽单体和二聚体拮抗剂
EP3201217A4 (en) * 2014-10-01 2018-07-18 Protagonist Therapeutics Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
WO2016205488A1 (en) * 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US10501546B2 (en) 2015-09-04 2019-12-10 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
US11634470B2 (en) * 2015-10-23 2023-04-25 Jai Prakash Integrin binding peptides and uses thereof
EP3377471A4 (en) * 2015-11-11 2019-11-20 Encycle Therapeutics, Inc. FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES
ES2903257T3 (es) 2015-12-09 2022-03-31 Scripps Research Inst Proteínas de fusión de inmunoglobulina de relaxina y métodos de uso
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109069635B (zh) 2016-02-04 2023-09-26 斯克利普斯研究所 人源化抗cd3抗体、偶联物及其用途
CN109195618A (zh) * 2016-03-23 2019-01-11 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
CA3042576A1 (en) 2016-11-11 2018-05-17 Encycle Therapeutics, Inc. Cyclic peptides multimers targeting .alpha.4.beta.7 integrin
MX2019013362A (es) * 2017-05-10 2020-08-17 Zealand Pharma As PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA.
US10278957B2 (en) 2017-09-11 2019-05-07 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020198682A1 (en) * 2019-03-28 2020-10-01 Protagonist Therapeutics, Inc. METHODS FOR SYNTHESIZING β-HOMOAMINO ACIDS
CA3146390A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3166637A1 (en) * 2020-01-10 2021-07-15 Protagonist Therapeutics, Inc. Methods for treating inflammatory bowel diseases with .alpha.4.beta.7 integrin antagonists
KR20220141808A (ko) 2020-01-15 2022-10-20 얀센 바이오테크 인코포레이티드 인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
EP4613761A2 (en) 2020-01-15 2025-09-10 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
US4724229A (en) * 1986-09-30 1988-02-09 Smithkline Beckman Corporation Arg-arg-arg-vasopressin antagonists
EP0578728B1 (en) * 1991-04-05 1998-07-01 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIIIa
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US5990084A (en) 1996-04-19 1999-11-23 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
EP0998309A1 (en) * 1997-07-11 2000-05-10 Innerdyne Medical, Inc. Methods and systems for preparing and sealing radiation delivery structures
US6818617B1 (en) 1997-08-15 2004-11-16 Temple University- Of The Commonwealth System Of Higher Education EC-3, an inhibitor of α4β1 and α4β7 integrins
EP1033983A1 (en) 1997-11-24 2000-09-13 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
WO2000006243A2 (en) * 1998-07-28 2000-02-10 Innerdyne, Inc. Absorbable brachytherapy and chemotherapy delivery devices and methods
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
AUPP616598A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Auxiliary for amide bond formation
AUPP660698A0 (en) 1998-10-21 1998-11-12 University Of Queensland, The A method of protein engineering
WO2000061580A1 (en) 1999-04-12 2000-10-19 Aventis Pharma Limited Substituted bicyclic heteroaryl compounds as integrin antagonists
WO2001068586A2 (en) 2000-03-14 2001-09-20 Novartis Ag α4β1 AND α4β7 INTEGRIN INHIBITORS
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
AUPS039702A0 (en) 2002-02-08 2002-03-07 University Of Queensland, The Common protein surface shapes and uses therefor
WO2004058307A1 (en) 2002-12-18 2004-07-15 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
US7723469B2 (en) 2003-11-05 2010-05-25 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
EP1695255B1 (en) 2003-12-19 2016-09-07 Applied Biosystems, LLC Methods and systems for protein and peptide evidence assembly
CA2552523C (en) 2004-01-09 2019-11-26 Pfizer Inc. Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam)
US8536140B2 (en) 2004-03-12 2013-09-17 Mti Meta Tech Inc. Methods for treating inflammatory bowel disease
NZ551934A (en) 2004-06-24 2009-09-25 Inst Medical W & E Hall Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins
WO2006062685A2 (en) 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1828243A2 (en) 2004-11-30 2007-09-05 Gastrotech Pharma A/S Growth hormone secretagogue receptor 1a ligands
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US9193790B2 (en) 2006-12-07 2015-11-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of antagonists of the interaction between HIV GP120 and A4B7 integrin
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2683145C (en) 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2009002947A2 (en) * 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN101990547A (zh) 2007-07-06 2011-03-23 瓦勒瑞萨欣Hsj有限合伙公司 Il-23受体拮抗剂以及其应用
WO2009039185A1 (en) * 2007-09-17 2009-03-26 The Trustees Of Columbia University In The City Of New York Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation
US20100280098A1 (en) 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
DE102009007381A1 (de) * 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
US8999935B2 (en) 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
CA2758264A1 (en) * 2009-04-08 2010-10-14 Takeda Pharmaceutical Company Limited Neuromedin u derivative
US9523073B2 (en) 2010-03-31 2016-12-20 Medical Diagnostic Laboratories, Llc Elisa for a naturally-occurring soluble truncated form of IL-23 receptor
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
US9169292B2 (en) 2011-06-14 2015-10-27 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
HK1199892A1 (en) 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
US20150157692A1 (en) 2012-05-23 2015-06-11 The University Of Chicago Methods of treating obesity
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
HK1219048A1 (zh) 2013-02-15 2017-03-24 Srx Cardio, Llc 前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(pcsk9)变构结合配体来调节低密度脂蛋白(ldl)血清水平
US20140294902A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
US20140294901A1 (en) 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide dimer antagonists
MX366341B (es) 2013-06-24 2019-07-05 Canbas Co Ltd Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.

Also Published As

Publication number Publication date
US20190248870A1 (en) 2019-08-15
AU2013329135A1 (en) 2015-04-30
US20160368966A1 (en) 2016-12-22
SG11201502812WA (en) 2015-05-28
JP6480865B2 (ja) 2019-03-13
EP2906584A4 (en) 2016-06-15
JP2015533833A (ja) 2015-11-26
CN105102470A (zh) 2015-11-25
SG10201702979SA (en) 2017-05-30
IL238123A0 (en) 2015-05-31
KR20150084808A (ko) 2015-07-22
WO2014059213A1 (en) 2014-04-17
HK1213583A1 (zh) 2016-07-08
EP2906584B1 (en) 2019-11-20
AU2018201599A1 (en) 2018-03-29
EP2906584A1 (en) 2015-08-19
NZ706909A (en) 2018-11-30
JP2019001825A (ja) 2019-01-10
US9273093B2 (en) 2016-03-01
AU2013329135B2 (en) 2018-02-01
CA2888479A1 (en) 2014-04-17
US20140193465A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
IN2015DN03039A (h)
HK1221233A1 (zh) 新型α4β7肽二聚体拮抗剂
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
IN2015MN00139A (h)
HK1206780A1 (en) Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
BR112015014876A2 (pt) composições e métodos para aperfeiçoar a solubilidade de rebaudiosídeo x
GB201203442D0 (en) Immunotherapeutic molecules and uses
SG10201810321PA (en) α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
IN2014DN08481A (h)
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
IN2015DN00636A (h)
EA201690461A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
IN2015DN00634A (h)
PH12015501687A1 (en) Novel binding proteins from pcsk9
EA201500371A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF АГЕНТЫ
PT2574682E (pt) Composição amiga do meio ambiente, adequada para curtimenta de couro, compreendendo zeólito
WO2014197805A3 (en) Molecular barcoding for multiplex sequencing
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
BR112017009289A2 (pt) métodos de administrar composições de amantadina
WO2013169631A3 (en) Wnt protein signalling inhibitors
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
PL401631A1 (pl) Nowe kompleksy rutenu, sposób ich wytwarzania oraz ich zastosowanie
CY1119470T1 (el) Γαλακταγωγες συνθεσεις με βαση φωσφατιδυλοσερινη